From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive pathways the preferred approach in the future. The key drivers include: growing patient demand for timely access to promising therapies, emerging science leading to fragmentation of treatment populations, rising payer influence on product accessibility, and pressure on pharma/investors to ensure sustainability of drug development. We also discuss a number of environmental changes that will enable an adaptive paradigm. A life‐span approach to bringing innovation to patients is expected to help address the perceived access vs. evidence trade‐off, help de‐risk drug development, and lead to better outcomes for patients.

[1]  Jan Bogaerts,et al.  Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Li-Huei Tsai,et al.  Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis , 2010, The Journal of Neuroscience.

[3]  Alan F. Karr,et al.  Deming, data and observational studies: A process out of control and needing fixing , 2013 .

[4]  Cassandra Willyard.  'Basket studies' will hold intricate data for cancer drug approvals , 2013, Nature Medicine.

[5]  H. Eichler,et al.  Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.

[6]  R J Glynn,et al.  Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development , 2011, Clinical pharmacology and therapeutics.

[7]  A. Breckenridge,et al.  The risks of risk aversion in drug regulation , 2013, Nature Reviews Drug Discovery.

[8]  Richard Platt,et al.  Launching PCORnet, a national patient-centered clinical research network , 2014, Journal of the American Medical Informatics Association : JAMIA.

[9]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[10]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[11]  Robert P Kocher,et al.  The calculus of cures. , 2014, The New England journal of medicine.

[12]  R. Katz,et al.  Regulatory innovation and drug development for early-stage Alzheimer's disease. , 2013, The New England journal of medicine.

[13]  Draft Guidance.  Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics DRAFT GUIDANCE , 2010 .

[14]  S. Stanley Young,et al.  Deming, data and observational studies , 2011 .

[15]  J. Woodcock,et al.  Evidence vs. Access: Can Twenty‐First‐Century Drug Regulation Refine the Tradeoffs? , 2012, Clinical pharmacology and therapeutics.

[16]  Programmierbarer Thermoblock,et al.  From industry , 1991 .

[17]  Lawrence D. Phillips,et al.  Benefit-risk methodology project: work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment , 2011 .

[18]  Roy Pardee,et al.  The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics , 2017, JMIR research protocols.

[19]  J. Coast.  Strategies for the economic evaluation of end-of-life care: making a case for the capability approach , 2014, Expert review of pharmacoeconomics & outcomes research.

[20]  B. Bloom,et al.  The Tension Between Cost Containment and the Underutilization of Effective Health Services , 1996, International Journal of Technology Assessment in Health Care.

[21]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[22]  Mark R. Trusheim,et al.  Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers , 2007, Nature Reviews Drug Discovery.

[23]  S. Schneeweiss.  Learning from big health care data. , 2014, The New England journal of medicine.

[24]  H. Leufkens,et al.  Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe , 2014, Clinical pharmacology and therapeutics.

[25]  J. Woodcock,et al.  Accelerated Access to Innovative Medicines for Patients in Need , 2014, Clinical pharmacology and therapeutics.

[26]  Bruce M Psaty,et al.  Mini-Sentinel and regulatory science--big data rendered fit and functional. , 2014, The New England journal of medicine.

[27]  Draft Guidance.  Adaptive Design Clinical Trials for Drugs and Biologics , 2010 .

[28]  Chris Henshall,et al.  ADAPTIVE APPROACHES TO LICENSING, HEALTH TECHNOLOGY ASSESSMENT, AND INTRODUCTION OF DRUGS AND DEVICES , 2014, International Journal of Technology Assessment in Health Care.

[29]  D. Sipp,et al.  Regulation: Sell help not hope , 2014, Nature.

[30]  Chris Henshall,et al.  HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION , 2013, International Journal of Technology Assessment in Health Care.

[31]  Panos Kanavos,et al.  Managed entry agreements for pharmaceuticals: the European experience , 2013 .

[32]  D. Roth.  A Third Seat at the Table: An Insider's Perspective on Patient Representatives , 2011, The Hastings Center report.

[33]  R B D'Agostino,et al.  A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials , 2013, Clinical pharmacology and therapeutics.

[34]  A Free-Market Approach to Clinical Data Gathering Is More Ethical , 2013, The American journal of bioethics : AJOB.

[35]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[36]  T. Schlich.  Railways, industry, and surgery--the introduction of risk management. , 2013, The New England journal of medicine.

[37]  P. Feldschreiber,et al.  Proposal for new European pharmaceutical legislation to permit access to custom‐made anti‐sense oligonucleotide medicinal products , 2014, British journal of clinical pharmacology.

[38]  J. Blay,et al.  VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). , 2014 .

[39]  Steven Pearson,et al.  Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers , 2010, Nature Reviews Drug Discovery.

[40]  Kristian Lampe,et al.  Practical tools and methods for health technology assessment in Europe: Structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA , 2009, International Journal of Technology Assessment in Health Care.

[41]  Daisaku Sato,et al.  New Governmental Regulatory System for Stem Cell—Based Therapies in Japan , 2014, Therapeutic innovation & regulatory science.